Drug
Generic Haart Triomune D4t
Generic Haart Triomune D4t: highest development phase Post-Market, developed by Cipla. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Cipla
Trials
| Drug | Phase | Indication |
|---|---|---|
| Generic HAART Triomune : d4T, 3TC, NVP NCT00380770 | Post-Market | HIV |
Latest
No recent events.
Follow Generic Haart Triomune D4t on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.